GlassScriptPhysician profile
Michael P Lewko
NPI 1730121799
$88,335.83
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $63K · 2020: $22K · 2021: $3,249 · 2022: $24.85 · 2023: $177 · 2024: $264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $441.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $83,316.84 | 2019-2021 | |
| Amgen INC. | $611.09 | 2019-2024 | Evenity |
| Abbvie INC. | $510.23 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $422.21 | 2019-2021 | |
| Pfizer INC. | $373.29 | 2019-2021 | |
| Janssen Biotech, INC. | $348.44 | 2019-2021 | |
| Lilly USA, LLC | $340.57 | 2019-2023 | Taltz |
| Ucb, INC. | $298.60 | 2019-2024 | Cimzia |
| E.R. Squibb & Sons, L.L.C. | $291.86 | 2019-2021 | |
| Genentech USA, INC. | $216.39 | 2019 | |
| Glaxosmithkline, LLC. | $193.88 | 2019-2023 | Benlysta |
| Biohaven Pharmaceuticals, INC. | $193.43 | 2021 | |
| Genzyme Corporation | $182.64 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $178.40 | 2019 | |
| Mallinckrodt Hospital Products INC. | $118.53 | 2020-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fidia Pharma USA INC. | $103.60 | 2019 | |
| Ferring Pharmaceuticals INC. | $101.22 | 2019-2021 | |
| Radius Health, INC. | $101.21 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2019 | |
| Aurinia Pharma U.S., INC. | $51.34 | 2023 | Lupkynis |
| Astrazeneca Pharmaceuticals LP | $48.09 | 2021-2022 | |
| Medexus Pharma, INC. | $34.85 | 2019 | |
| Antares Pharma, INC. | $27.36 | 2019 | |
| Avion Pharmaceuticals | $27.30 | 2020 | |
| Sobi, INC | $26.41 | 2019 | |
| Alexion Pharmaceuticals, INC. | $25.73 | 2020 | |
| Organon LLC | $24.75 | 2023 | Renflexis, Hadlima |
| Ultragenyx Pharmaceutical INC. | $15.00 | 2021 | |
| Zyla Life Sciences, INC. | $14.24 | 2019 | |
| Boston Scientific Corporation | $14.16 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.39 | 2019 | |
| Merck Sharp & Dohme LLC | $11.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Lewko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.